Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8935 results

  1. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [TSID12351]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  7. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  8. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 3 March 2026.

    Technology appraisal guidance
    In consultation

  10. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 February 2026.

    Technology appraisal guidance
    In consultation

  11. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  12. Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

    Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis

    Evidence summary
    Published
    7 October 2014

  13. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014

  14. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  15. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 January 2013